Gestational Diabetes Market is segmented By Treatment (Insulin Therapy, Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Oral ....
Market Size in USD
CAGR8.9%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 8.9% |
Market Concentration | Medium |
Major Players | Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co., Inc., F. Hoffmann-La Roche Ltd |
The gestational diabetes market is estimated to be valued at USD 9.4 Bn in 2024 and is expected to reach USD 17.1 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031. An increasing number of risk factors associated with gestational diabetes such as rising obesity levels, older maternal age during pregnancy and sedentary lifestyles are contributing to the rising disease incidence. However, the lack of symptoms in early stages of gestational diabetes remains a major challenge.